Interactions of multitargeted kinase inhibitors and nucleoside drugs: Achilles heel of combination therapy?

Molecular Cancer Therapeutics

Volumn 14, Issue 1, 2015, Pages 236-245

  Damaraju, Vijaya L ^a   Kuzma, Michelle ^a   Mowles, Delores ^a   Cass, Carol E ^a   Sawyer, Michael B ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; GEMCITABINE; PAZOPANIB; SUNITINIB; DEOXYCYTIDINE; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; INDOLE DERIVATIVE; NUCLEOSIDE TRANSPORTER; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE;

A549 CELL LINE; ARTICLE; CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; NUCLEOSIDE TRANSPORT; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; DRUG POTENTIATION; METABOLISM; NEOPLASM; TUMOR CELL LINE;

CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG SYNERGISM; HUMANS; IMIDAZOLES; INDAZOLES; INDOLES; NEOPLASMS; NUCLEOSIDE TRANSPORT PROTEINS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; SULFONAMIDES;

EID: 84922341460     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0337     Document Type: Article

References (58)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
3. Appelmann I, Liersch R, Kessler T, Mesters RM, Berdel WE. Angiogenesis inhibition in cancer therapy: platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) and their receptors: biological functions and role in malignancy. Recent Results Cancer Res 2010;180:51-81.
4. Hellberg C, Ostman A, Heldin CH. PDGF and vessel maturation. Recent Results Cancer Res 2010;180:103-14.
5. Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol 2014;32:1412-8.
6. King JW, Lee SM.Axitinib for the treatment of advanced non-small-cell lung cancer. Expert Opin Investig Drugs 2013;22:765-73.
7. Nishida T, Doi T, Naito Y. Tyrosine kinase inhibitors in treatment of unresectable or metastatic gastrointestinal stromal tumors. Expert Opin Pharmacother 2014;22:1-11.
8. Majem M, Pallares C. An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents. Clin Transl Oncol 2013;15:343-57.
9. Kindler HL, Ioka T, Richel DJ, Bennouna J, Letourneau R, Okusaka T, et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 2011;12:256-62.
10. Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013;14:552-62.
11. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R,Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369:722-31.
12. Plummer R, Madi A, Jeffels M, Richly H, Nokay B, Rubin S, et al. A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol 2013;71:93-101.
13. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378:1931-9.
14. Spano JP, Moore MJ, Pithavala YK, Ricart AD, Kim S, Rixe O. Phase I study of axitinib (AG-013736) in combinationwith gemcitabine in patients with advanced pancreatic cancer. Invest New Drugs 2012;30:1531-9.
15. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061-8.
16. van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879-86.
17. Blackhall FH, O'Brien M, Schmid P, Nicolson M, Taylor P, Milenkova T, et al. A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer. J Thorac Oncol 2010;5:1285-8.
18. Fountzilas G, Bobos M, Kalogera-Fountzila A, Xiros N, Murray S, Linardou H, et al. Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of theHellenic Cooperative Oncology Group with biomarker evaluation. Cancer Invest 2008;26:784-93.
19. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004;22:777-84.
20. Philips GK, Halabi S, Sanford BL, Bajorin D, Small EJ. A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102. BJU Int 2008;101:20-5.
21. Philips GK, Halabi S, Sanford BL, Bajorin D, Small EJ. A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Ann Oncol 2009;20:1074-9.
22. Awasthi N, Schwarz MA, Schwarz RE. Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer. HPB 2011;13:597-604.
23. Richly H, Maute L,Heil G, Russel J, Jager E. Prospective randomized phase II trial with gemictabine versus gemcitabine plus sunitinib in advanced pancreatic cancer. J Clin Oncol 31, 2013 (suppl; abstr 4035).
24. Spano JP, Chodkiewicz C, Maurel J, Wong R, Wasan H, Barone C, et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 2008;371:2101-8.
25. Young JD, Yao SY, Baldwin JM, Cass CE, Baldwin SA. The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29. Mol Aspects Med 2013;34:529-47.
26. Damaraju VL, Sawyer MB, Mackey JR, Young JD, Cass CE. Human nucleoside transporters: biomarkers for response to nucleoside drugs. Nucleosides Nucleotides Nucleic Acids 2009;28:450-63.
27. Zhang J, Visser F, King KM, Baldwin SA, Young JD, Cass CE. The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer Metastasis Rev 2007;26:85-110.
28. Huang M, Wang Y, Cogut SB, Mitchell BS, Graves LM. Inhibition of nucleoside transport by protein kinase inhibitors. J Pharmacol Exp Ther 2003;304:753-60.
29. Huang M,Wang Y, Collins M, Gu JJ, Mitchell BS, Graves LM. Inhibition of nucleoside transport by p38 MAPK inhibitors. J Biol Chem 2002;277:28364-7.
30. Leisewitz AV, Zimmerman EI, Jones SZ, Yang J, Graves LM. Imatinib-resistant CML cells have low ENT activity but maintain sensitivity to gemcitabine. Nucleosides Nucleotides Nucleic Acids 2008;27:779-86.
31. Woodahl EL, Wang J, Heimfeld S, Ren AG, McCune JS. Imatinib inhibition of fludarabine uptake in T-lymphocytes. Cancer Chemother Pharmacol 2008;62:735-9.
32. Damaraju VL, Scriver T, Mowles D, Kuzma M, Ryan AJ, Cass CE, et al. Erlotinib, gefitinib, and vandetanib inhibit human nucleoside transporters and protect cancer cells from gemcitabine cytotoxicity. Clin Cancer Res 2014;20:176-86.
33. Vickers MF, Kumar R, Visser F, Zhang J, Charania J, Raborn RT, et al. Comparison of the interaction of uridine, cytidine, and other pyrimidine nucleoside analogues with recombinant human equilibrative nucleoside transporter 2 (hENT2) produced in Saccharomyces cerevisiae. Biochem Cell Biol 2002;80:639-44.
34. Zhang J, Visser F, Vickers MF, Lang T, Robins MJ, Nielsen LP, et al. Uridine binding motifs of human concentrative nucleoside transporters 1 and 3 produced in Saccharomyces cerevisiae. Mol Pharmacol 2003;64:1512-20.
35. Vickers MF, Zhang J, Visser F, Tackaberry T, Robins MJ, Nielsen LP, et al. Uridine recognition motifs of human equilibrative nucleoside transporters 1 and 2 produced in Saccharomyces cerevisiae. Nucleosides Nucleotides Nucleic Acids 2004;23:361-73.
36. Visser F, Vickers MF, Ng AM, Baldwin SA, Young JD, Cass CE. Mutation of residue 33 of human equilibrative nucleoside transporters 1 and 2 alters sensitivity to inhibition of transport by dilazep and dipyridamole. J Biol Chem 2002;277:395-401.
37. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
38. Segel IH. Enzyme Kinetics. New York, NY: John Wiley and Sons; 1975.
39. Ayllon J, Beuselinck B, Morel A, Barrascout E, Medioni J, Scotte F, et al. Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma. Cancer Invest 2011;29:282-5.
40. Dranitsaris G, Schmitz S, Broom RJ. Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy. J Cancer Res Clin Oncol 2013;139:1917-26.
41. Kruck S, Merseburger AS, Gakis G, Kramer MW, Stenzl A, Kuczyk MA. An update on themedical therapy of advanced metastatic renal cell carcinoma. Scand J Urol Nephrol 2008;42:501-6.
42. Mankal P, O'Reilly E. Sunitinib malate for the treatment of pancreas malignancies-where does it fit? Expert Opin Pharmacother 2013;14:783-92.
43. Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G, et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 2004;104:2940-2.
44. Elkind NB, Szentpetery Z, Apati A, Ozvegy-Laczka C, Varady G, Ujhelly O, et al. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res 2005;65:1770-7.
45. Erlichman C, Boerner SA, Hallgren CG, Spieker R, Wang XY, James CD, et al. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res 2001;61:739-48.
46. Mi Y, Lou L. ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein. Br J Cancer 2007;97:934-40.
47. Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 2008;68:7905-14.
48. Shi Z, Peng XX, Kim IW, Shukla S, Si QS, RobeyRW, et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 2007;67:11012-20.
49. Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009;15:4220-7.
50. McKillop D, Partridge EA, Kemp JV, Spence MP, Kendrew J, Barnett S, et al. Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Mol Cancer Ther 2005;4:641-9.
51. Haura EB, Sommers E, Song L, Chiappori A, Becker A. A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance. J Thorac Oncol 2010;5:1806-14.
52. Gotink KJ, Broxterman HJ, Labots M, deHaas RR, Dekker H, Honeywell RJ, et al. Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res 2011;17:7337-46.
53. Chen Y, Tortorici MA, Garrett M, Hee B, Klamerus KJ, Pithavala YK. Clinical pharmacology of axitinib. Clin Pharmacokinet 2013;52:713-25.
54. Reyner EL, Sevidal S, West MA, Clouser-Roche A, Freiwald S, Fenner K, et al. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions. Drug Metab Dispos 2013;41:1575-83.
55. Paproski RJ, Ng AM, Yao SY, Graham K, Young JD, Cass CE. The role of human nucleoside transporters in uptake of 3′-deoxy-3′-fluorothymidine. Mol Pharmacol 2008;74:1372-80.
56. Barthel H, Cleij MC, Collingridge DR, Hutchinson OC, Osman S, He Q, et al. 3′-deoxy-3′-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003;63:3791-8.
57. Liu G, Jeraj R, Vanderhoek M, Perlman S, Kolesar J, Harrison M, et al. Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate. Clin Cancer Res 2012;17:7634-44.
58. Zhao S, Kuge Y, Zhao Y, Takeuchi S, Hirata K, Takei T, et al. Assessment of early changes in 3H-fluorothymidine uptake after treatment with gefitinib in human tumor xenograft in comparison with Ki-67 and phospho-EGFR expression. BMC Cancer 2013;13:525.